Prediction: $100 per Month Invested in Eli Lilly (LLY) Stock Will Be Worth This Much by 2030

So you're thinking of investing in Eli Lilly (NYSE: LLY) stock and you're wondering how it will perform by 2030 -- about four years from now. No one can know exactly how any stock will perform over a certain period. Still, we can certainly make an educated guess.

We might start by looking at how the stock has performed in the past:

Period	Average Annual Gain
Past 3 years	32.37%
Past 5 years	39.20%
Past 10 years	33.02%
Past 15 years	26.78%

Source: Morningstar.com, as of Oct. 27, 2026.

It's worth keeping in mind that these growth rates are far above the long-term average annual gains for the overall stock market, which have been closer to 10%.

They're steep in large part because Lilly's home to some blockbuster GLP-1 weight-loss drugs such as Mounjaro and Zepbound. Those robust sales may continue for the foreseeable future, with Morgan Stanley forecasting that the global market for GLP-1 drugs could more than double between 2025 and 2035, to $190 billion. There's competition, though, such as from Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy.

To be somewhat conservative, let's not assume annual growth topping 30%. Let's go with, say, 25% instead. Let's also assume you invest $100 per month (that's $1,200 annually) in Eli Lilly stock for four years. Come late 2030, what will your stake be worth? The answer is... close to $8,000. You would have invested $4,800 and the rest would be your gain -- some 67% over four years.

Here's another consideration: At recent levels, Eli Lilly stock may be overvalued. Its price-to-sales ratio, for example, is 14.4, above its five-year average of 13.3. Its price-to-earnings (P/E) ratio of 43 is below its five-year average of 58, but all of these numbers are on the steep side. The current valuation may actually be reasonable -- assuming all goes well for the company. But a pullback is certainly possible, and that would affect our growth projection.

Eli Lilly is well worth considering for your portfolio, but learn more about it first.

Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.